Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-guided subcutaneous vedolizumab de-escalation in inflammatory bowel disease
NL-OMON51420Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Cost-effectiveness of TDM-guided de-escalation versus standard dosing. Started Feb 2023; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON51420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51420.